PUBLIC COMPANY
save$TCRXTScan Therapeutics, Inc.
$TCRXWaltham, MA, USupdated 2mo ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 12Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
- phase3A Phase 3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
- phase1A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
- phase1A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
- —A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
- —A Long Term Follow-up Study of TScan TCR-T Products
🐶 Hiring Signal
News
- Ionis’ rare neurology drug approved; Pfizer inks an ADC dealZanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.biopharma_dive · 29d ago
- Amgen cans its TScan partnership; Amylyx reveals $350M offeringPlus news about BioArctic, Enveda, Georgiamune, Kynexis, Tolerance Bio and Network Bio. Amgen puts the "can" in TScan: Amgen is terminating its partnership with TScan Therapeutics, the Waltham, MA-…endpoints · 1mo ago
Data sources
last refreshed 52m ago
Found something off?
comments(0)
5-min edit window · permanent after that